High-dose N-acetylcysteine in the prevention of COPD exacerbations: Rationale and design of the PANTHEON study

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 10, Issue 2, 2013, Pages 164-171

  Zheng, Jin Ping ^a   Wen, Fu Qiang ^b   Bai, Chun Xue ^c   Wan, Huan Ying ^d   Kang, Jian ^e   Chen, Ping ^f   Yao, Wan Zhen ^g   Ma, Li Jun ^h   Xia, Qi Kui ^c   Gao, Yi ^a   Zhong, Nan Shan ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e CHINA MEDICAL UNIVERSITY   (China)

^f GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^g PEKING UNIVERSITY THIRD HOSPITAL   (China)

^h HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Anti inflammation; Anti oxidant; COPD; Exacerbation; ICS; Mucolytics; N Acetylcysteine; Quality of Life

Indexed keywords

ACETYLCYSTEINE; PLACEBO;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ACETYLCYSTEINE; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; EXPECTORANTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RESEARCH DESIGN; TIME FACTORS; VITAL CAPACITY;

EID: 84875866752     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2012.732628     Document Type: Article

References (37)

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available from: http://www.goldcopd.org/.
2. Poole PJ, Black PN. Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents. Am J Respir Med 2003; 2(5):367-370.
3. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153(5):1530-1535.
4. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003; 48(12):1204-1213.
5. Zheng J-P, Kang J, Huang S-G, Chen P, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): A randomized placebocontrolled study. Lancet 2008; 371:2013-2018.
6. Blackwell TS, Blackwell TR, Holden EP, Christman BW, Christman JW. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J Immunol1996; 157(4):1630-1637.
7. Lappas M, Permezel M, Rice GE. N-Acetyl-cysteine inhibits phospholipid metabolism, proinflammatory cytokine release, protease activity, and nuclear factor-kappaB deoxyribonucleic acid-binding activity in human fetal membranes in vitro. J Clin Endocrinol Metab 2003; 88(4):1723-1729.
8. van Overveld FJ, Demkow U, Górecka D, de Backer WA, Zielinski J. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine. J Physiol Pharmacol 2005; 56 Suppl 4:135-142.
9. Ekberg-Jansson A, Larson M, MacNee W, Tunek A, Wahlgren L, Wouters EF, Larsson S. N-isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis. Eur Respir J 1999; 13:829-834.
10. Sadowska AM, Manuel-Y-Keenoy B, De Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: Discordant in vitro and in vivo doseeffects: A review. Pulm Pharmacol Ther 2007; 20:9-22.
11. Rubio ML, Martin-Mosquero MC, Ortega M, Peces-Barba G, González-Mangado N. Oral N-acetylcysteine attenuates elastase-induced pulmonary emphysema in rats. Chest 2004; 125(4):1500-1506.
12. Urban T, Akerlund B, Jarstrand C, Lindeke B. Neutrophil function and glutathione-peroxidase (GSH-px) activity in healthy individuals after treatment with N-acetyl-L-cysteine. Biomed Pharmacother 1997; 51(9):388-390.
13. Riise GC, Qvarfordt I, Larsson S, Eliasson V, Andersson BA. Inhibitory eff ect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human oropharyngeal epithelial cells in vitro. Respiration 2000; 67(5):552-558.
14. Mata M, Morcillo E, Gimeno C, Cortijo J. N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol 2011; 82(5):548-555.
15. Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, MacNee W. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005; 60(4):293-300.
16. Decramer M, Rutten-van Molken M, Dekhuijzen PNR, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomised placebo-controlled trial. Lancet 2005; 365:1552-1560.
17. Dekhuijzen PNR. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004; 23:629-636.
18. National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: National Clinical Guideline Centre. Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/English, 2010.
19. Gerrits CMJM, Herings RMC, Laufkens HGM, et al. N-Acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 2003; 21:795-798.
20. Zuin R, Palamidese A, Negrin R, et al. High dose N-Acetylcysteine in Patients with Exacerbations of Chronic Obstructive Pulmonary Diseases. Clin Drug Invest 2005; 25(6):401-408.
21. Moher D, Schulz KF, Altman DG, et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357:1191-1194.
22. Declaration of Helsinki World Medical Association. Available from: http://www.wma.net/e/ethicsunit/helsinki.htm.
23. International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP).ICH GCP (E6): Adopted by CPMP, July 1996, issued as CPMP/ICH/135/95/Step5, Explanatory Note and Comments to the above, issued as CPMP/768/97.
24. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA, Manitoba W. Antibiotic therapy in exacerbation of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196-204.
25. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56:880-887.
26. Crapo RO, Hankinson JL, Irvin C, et al. American Thoracic Society. Standardization of spirometry-1994 update. Am J Respir Crit Care Med 1995; 152: 1107-1136.
27. Quanjer PH. Standardized lung function testing. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16:5-40.
28. Zheng JP, Zhong NS. Normative values for pulmonary function testing in Chinese adults. Chin Med J 2002; 115:50-54.
29. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, Make BJ, Rabe KF, Rennard SI, Sciurba FC, Silverman EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ. Chronic obstructive pulmonary disease phenotypes: the future of COPD.Am J Respir Crit Care Med 2010; 182(5):598-604.
30. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslem TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-1303.
31. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, for the UPLIFT Study Investigators. A 4-year trial of tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med 2008; 359:1543-1554
32. Zheng JP, Zhong NS, Jiang M, et al. Carbocisteine for acute exacerbations of COPD - Authors' reply. Lancet 2008; 372:1631-1632.
33. Vestbo J, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). ERJ 2008; 31:869-873.
34. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:1128-1138.
35. Liu S, Zhou Y, Wang X, Wang D, Zheng J, Zhong N, Ran P, et al. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. Thorax 2007; 62:889-897.
36. Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, Kesten S. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008; 31: 742-750.
37. Zhang F-Q, Zheng J-P, Wang J-H, Lu W-B, Wu R-X, Li X-S, Xian Q-Z, Gao H, Jiang M. Comparison of lung volume response with airflow response to bronchodilator in patients with chronic obstructive pulmonary disease. Zhong Hua Jie He Hu Xi Za Zhi (Chin J Tuberc Respir Dis) 2010; 33(2):109-113.